$28.41
5.71% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Veracyte Inc Stock price

$30.13
-3.43 10.22% 1M
-3.67 10.84% 6M
-9.47 23.91% YTD
+9.62 46.90% 1Y
+0.61 2.07% 3Y
+9.19 43.89% 5Y
+22.69 304.97% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.57 1.93%
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Key metrics

Market capitalization $2.35b
Enterprise Value $2.11b
P/E (TTM) P/E ratio 98.30
EV/FCF (TTM) EV/FCF 33.06
EV/Sales (TTM) EV/Sales 4.73
P/S ratio (TTM) P/S ratio 5.27
P/B ratio (TTM) P/B ratio 1.99
Revenue growth (TTM) Revenue growth 23.46%
Revenue (TTM) Revenue $445.76m
EBIT (operating result TTM) EBIT $23.73m
Free Cash Flow (TTM) Free Cash Flow $63.81m
Cash position $289.44m
EPS (TTM) EPS $0.31
P/E forward 60.43
P/S forward 4.81
EV/Sales forward 4.32
Short interest 4.72%
Show more

Is Veracyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Veracyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Veracyte Inc forecast:

10x Buy
77%
2x Hold
15%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Veracyte Inc forecast:

Buy
77%
Hold
15%
Sell
8%

Financial data from Veracyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
446 446
23% 23%
100%
- Direct Costs 156 156
13% 13%
35%
289 289
30% 30%
65%
- Selling and Administrative Expenses 174 174
17% 17%
39%
- Research and Development Expense 68 68
21% 21%
15%
47 47
169% 169%
11%
- Depreciation and Amortization 23 23
20% 20%
5%
EBIT (Operating Income) EBIT 24 24
304% 304%
5%
Net Profit 24 24
132% 132%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Veracyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veracyte Inc Stock News

Neutral
Business Wire
9 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer.
Neutral
Business Wire
15 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25.
Neutral
Seeking Alpha
about one month ago
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively with 23% revenue growth and strong cash flow, yet 2025 will be critical for transitioning to a stable, profit-generating leader. Regulatory uncertainties, Afirma's growth deceleration, and potential...
More Veracyte Inc News

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marc Stapley
Employees 824
Founded 2006
Website www.veracyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today